Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2ZUXK)

• Drug Name: Lu-AA34893 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Anxiety disorder	6B00-6B0Z	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DM2ZUXK

Molecule-Related Drug Atlas

Drug(s) Targeting Serotonin transporter (SERT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[3]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[4]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[5]
Vortioxetine	DM6F1PU	Major depressive disorder	6A70.3	Approved	[6]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[7]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[8]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[9]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[5]
Nortriptyline	DM4KDYJ	Depression	6A70-6A7Z	Approved	[5]
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[5]

Drug(s) Targeting 5-HT receptor (5HTR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[10]
Paliperidone	DM7NPJS	Psychotic disorder	6A20-6A25	Approved	[11]
Ramosetron	DMH7GN8	Diarrhea-predominant irritable bowel syndrome	DD91.01	Approved	[10]
Pizotyline	DMV74ZH	Headache	8A80-8A84	Approved	[11]
Tandospirone	DMPHWU6	Anxiety disorder	6B00-6B0Z	Approved	[10]
Nafronyl	DMVMQ1L	Cerebrovascular ischaemia	8B1Z	Approved	[11]
ITI-007	DMUQ1DO	Depression	6A70-6A7Z	Phase 3	[12]
Fenfluramine	DM0762O	Dravet syndrome	8A61.11	Phase 3	[13]
MIN-117	DMSLIW6	Major depressive disorder	6A70.3	Phase 2	[12]
SEP--4199	DMA12HB	Bipolar disorder	6A60	Phase 2	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT receptor (5HTR)	TT85JO3	NOUNIPROTAC	Modulator	[2]
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Modulator	[2]

References

• [1] ClinicalTrials.gov (NCT00622245) Efficacy and Safety of Lu AA34893 in Patients With Bipolar Depression. U.S. National Institutes of Health.
• [2] Encyclopedia of Psychopharmacology. Ian Stolerman. 2010. Page(105).
• [3] Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
• [4] Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [7] Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
• [8] Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
• [9] Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
• [10] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
• [14] ClinicalTrials.gov (NCT03543410) A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression. U.S. National Institutes of Health.